

# ATLEY INSTALLS ATLEY C100 AT WORLD CLASS NUCLEAR MEDICINE RESEARCH INSTITUTE ARRONAX

Gothenburg, Sweden – 17 February 2025 – Atley Solutions has successfully installed an Atley C100 module at Arronax, a world-leading nuclear medicine research institute in Nantes, France. This installation marks a significant milestone in the industrialization of Astatine-211 (At-211) radiopharmaceutical manufacturing, enabling Arronax to scale up production while maintaining the highest safety standards.

## Arronax is playing a key role in advancing At-211 based drug development

Arronax is one of Europe's foremost producers of At-211, a promising radionuclide for targeted alpha therapy in oncology. The institute plays a key role in advancing At-211-based drug development, and the installation of the Atley C100 module further strengthens Nantes' position as a major hub for At-211 research and manufacturing.


*"Increasing the availability of At-211 to researchers and drug developers is key for the clinical translation of At-211-based drug candidates in Europe" said Ferid Haddad, Director of Arronax. "we are impatient to assess the gains Atley's C100 module can bring to our operation"*

## Advancing At-211 Manufacturing with the Atley C100

The Atley C100 is the world's first and only commercially available manufacturing system specifically designed for At-211 radiopharmaceuticals. By automating and industrializing both the dry distillation purification process and At-211 radiolabeling processes, the module enhances production capacity while ensuring operator safety and regulatory compliance.

This installation at Arronax represents a major scientific and commercial achievement for Atley, reinforcing its mission to bridge the gap between research and industrial applications.

*"Nantes has long been a European hub for At-211 research, alongside our home base in Gothenburg, Sweden," said Milton Lönnroth, CEO of Atley Solutions. "Arronax's groundbreaking work in nuclear medicine has been instrumental in advancing At-211 applications, and we are proud to support their efforts with the Atley C100 module."*



## About Atley Solutions

Atley Solutions is the global leader in commercial products and services for the development, clinical evaluation and commercialisation of At-211 radiopharmaceuticals. The Atley C100 is the world's only commercial module for automated manufacturing of At-211 radiopharmaceuticals, addressing key challenges in radionuclide production and supply chain scalability. In addition to its cutting-edge technology, Atley provides radiopharmaceutical development services and is a leading supplier of At-211.

## About Arronax

At the heart of a rich nuclear medicine ecosystem, Arronax is a premier research institute based in Nantes, France, dedicated to advancing radiopharmaceutical innovation. Renowned for its pioneering work with Astatine-211, Arronax specializes in the production of medical isotopes and radiopharmaceuticals for cutting-edge cancer treatments. Through state-of-the-art facilities and a commitment to scientific excellence, Arronax continues to drive advancements in targeted alpha therapy, bringing promising new treatments closer to clinical use.

## Contact Information

For more information about Atley Solutions or the Atley C100 please contact:

### Milton Lönnroth

Co-Founder & CEO

Atley Solutions AB

Phone: +46 (0) 704 34 84 57

Email: [info@atley.com](mailto:info@atley.com)